4DMedical Secures US$100+ Million Funding to Accelerate U.S. Expansion and increase Technology Dominance in Software-Based Lung Imaging

Core Insights - 4DMedical has secured over US$100 million (AU$150 million) in new institutional funding to enhance the adoption of its CT:VQ™ imaging product and to advance research and development efforts [1][2][3] Funding and Financial Position - The funding will enable 4DMedical to scale hospital deployments of its CT:VQ™ product and support early adopters at prestigious institutions such as Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health [1][2] - Following the funding round, 4DMedical reported a pro forma cash position exceeding US$130 million (AU$200 million), which will facilitate the company's U.S. expansion strategy [4] Product and Technology - CT:VQ™ is an FDA-cleared SaaS technology that provides ventilation and perfusion insights from CT imaging, which has been rapidly adopted by leading U.S. academic medical centers within four months of its clearance [2][9] - The technology is designed to integrate seamlessly into existing hospital workflows, enhancing operational efficiency and decision-making for clinicians [5][10] Strategic Partnerships and Market Position - 4DMedical is focusing on strategic partnerships, including collaboration with Philips, to support broader adoption of its technology [5] - The company aims to deepen partnerships and dominate the global marketplace for software-based lung imaging tools, reflecting its technological leadership and growth potential in the U.S. [3][8] Research and Development - Ongoing research and development efforts are aimed at expanding 4DMedical's technology leadership and product portfolio in functional lung imaging [8] - The company is committed to providing customer success, training, and technical support to ensure effective integration of CT:VQ™ into clinical workflows [8]